PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Mengjie Liu

Second Affiliated Hospital of Xi'an Jiaotong University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs1 Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · JOURNAL ARTICLE

Time to benefit of perioperative immunotherapy among patients with resectable non-small-cell lung cancer

BMC Cancer

Rigorous meta-analysis of 8 RCTs with reconstructed individual patient data and quantitative time-to-benefit modelling provides robust evidence on treatment duration, though findings are primarily analytical rather than from a new primary trial.

Strong EvidenceXiaohui Jia Wenming Bian Jingyi Li

Reported

Sample size5123

TTB for 1% EFS risk reduction1.02 months

TTB for 10% EFS risk reduction9.01 months

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support